Skip to main content

Table 4 Prognostic implications of switches of the antifibrotics in patients with IPF by univariate and multivariate Cox-proportion analyses

From: Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Predictor HR 95% CI p value   HR 95% CI p value
Univariate analysis Multivariate analysis 1
Age, year 1.024 1.000–1.050 0.0481 Age, year 1.003 0.978–1.029 0.8402
Gender, male 1.054 0.652–1.624 0.8218 Gender, male 1.455 0.905–2.438 0.1365
History of AE, yes 2.413 1.518–3.677 < 0.0001 History of AE, yes 1.062 0.602–1.777 0.8268
Pirfenidone 1.002 0.694–1.425 0.9892 BMI, per 1 kg/m2 increase 0.956 0.904–1.009 0.1051
Period: Diagnosis-administration 1.001 0.996–1.005 0.7124 FVC, per 1% increase 0.978 0.967–0.989 0.0001
BMI, per 1 kg/m2 increase 0.905 0.860–0.953 0.0001 LTOT, yes 1.774 1.205–2.590 0.0032
FVC,per 1% increase 0.970 0.959–0.980 < 0.0001 Patients with IPF who switched antifibrotics 0.392 0.221–0.656 0.0007
FEV1, per 1% increase 0.989 0.979–0.999 0.0261 Multivariate analysis 2
FEV1/FVC, per 1% increase 1.061 1.038–1.089 < 0.0001 Age, year 1.005 0.979–1.032 0.7131
DLCO, per 1% increase 0.974 0.962–0.986 < 0.0001 Gender, male 1.536 0.940–2.618 0.0992
TP, per 1 g/dl increase 0.978 0.763–1.271 0.8647 History of AE, yes 1.214 0.684–2.267 0.5247
Alb, per 1 g/dl increase 0.601 0.411–0.896 0.0105 BMI, per 1 kg/m2 increase 0.940 0.883–0.997 0.0440
KL-6, per 1 U/ml increase 1.000 1.000–1.000 0.0003 FVC, per 1% increase 0.980 0.968–0.991 0.0007
SP-D, per 1 ng/ml increase 1.001 1.000–1.002 0.0510 KL-6, per 1 U/ml increase 1.000 1.000–1.000 0.0217
LTOT, yes 2.575 1.847–3.574 < 0.0001 LTOT, yes 1.660 1.103–2.468 0.0135
Patients with IPF who switched antifibrotics 0.318 0.182–0.506 < 0.0001 Patients with IPF who switched antifibrotics s 0.374 0.206–0.638 0.0006
Switching antifibrotics (time dependent covariate) 0.895 0.517–1.550 0.692     
  1. AE acute exacerbation, BMI body mass index, FVC forced vital capacity, FEV1.0 forced expiratory volume in 1.0 s, DLCO diffuse capacity of the lung for carbon monoxide, LTOT long-term oxygen therapy